Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12480251 | 0.82 | KMT2A (0.34) | KMT2AATMDGAT1LMNAXBP1 | |
| SCHEMBL12481481 | 0.79 | KMT2A (0.33) | KMT2AATMDGAT1LMNAXBP1 | |
| SCHEMBL16649861 | 0.77 | PBRM1 (0.32) | — | |
| SCHEMBL12481336 | 0.73 | LMNA (0.36) | KMT2AATMDGAT1LMNAXBP1 | |
| SCHEMBL3324835 | 0.72 | KDM4E (0.41) | KMT2ALMNA | |
| SCHEMBL28074401 | 0.69 | KMT2A (0.50) | KMT2AATMDGAT1LMNA | |
| SCHEMBL2581821 | 0.69 | CES2 (0.48) | KMT2AATMDGAT1LMNAXBP1 | |
| SCHEMBL6052818 | 0.67 | CASP1 (0.43) | KMT2AATMDGAT1 | |
| SCHEMBL811777 | 0.66 | KMT2A (0.52) | KMT2AATMDGAT1LMNA | |
| SCHEMBL2584915 | 0.63 | DGAT1 (0.47) | KMT2AATMDGAT1LMNAXBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | KMT2A 4723/4885ATM 4141/4885DGAT1 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.